A Moncton-based company which analyzes breath samples to screen for diseases has received federal funding to continue its research.
Picomole will receive $818,000 through ACOA (Atlantic Canada Opportunities Agency) to develop a diagnostic device for lung cancer.
CEO Stephen Graham says the company is now building a better version of a breath analyzer.
“(The funding) will allow us to improve upon our accuracy and move into larger regulatory clinical trials with Health Canada and the FDA in the United States.”
#Moncton-based Picomole Inc. will receive $818K in federal funding to develop diagnostic device for lung cancer. MP Ginette Petitpas Taylor tests the device today at company lab on Halifax Street. #nb #nbnews #cdnpoli #canpoli pic.twitter.com/51YEf1ZHUv
— 91.9The Bend News (@919TheBendNews) February 12, 2019
Graham adds Picomole has just been accepted into a four month residency at the Massachusetts Institute of Technology which will give the company unlimited access to Canadian entrepreneurs in New England and global medical technology and pharmaceutical companies.
Graham thinks disease screening and diagnosis through breath analysis is the future.
He believes Picomole is moving into a global leadership position in this field.
